Management of diabetes mellitus with insulin lispro

Masami Tanaka, Hiroshi Itoh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Insulin lispro (Humalog®) is a recombinant human insulin analogue with reversed amino acids at position 28 and 29 on the insulin B-chain (Lys(B28), Pro(B29)). It has a faster onset and shorter duration of glucose-lowering activity than regular human insulin (RHI), which is a great advantage. Insulin lispro can be injected immediately before meals or even after meals. This short injection-meal interval contributes greatly to convenience, flexibility, treatment compliance, and patients' quality of life, which in turn lead to better glycemic control. Numerous clinical trials have demonstrated that insulin lispro, alone or as mixture-25 or -50, controls postprandial blood glucose and stabilizes diurnal variation satisfactorily. The risk of hypoglycemia, including severe or nocturnal episodes, was lower in insulin lispro users than in RHI users. This insulin might be suitable for type 1 diabetic patients, especially when using an insulin pump. Combination therapy of lispro with a sulphonylurea or glargine is safe and efficacious. Several pharmacoeconomic studies have revealed the usefulness of this insulin.

Original languageEnglish
Pages (from-to)275-289
Number of pages15
JournalClinical Medicine Insights: Therapeutics
Volume3
DOIs
Publication statusPublished - 2011

Fingerprint

Insulin Lispro
Diabetes Mellitus
Insulin
Insulin, Regular, Human
Meals
Pharmaceutical Economics
Patient Compliance
Hypoglycemia
Blood Glucose
Quality of Life
Clinical Trials
Amino Acids
Glucose
Injections
Therapeutics

Keywords

  • Diabetes mellitus
  • Hypoglycemia
  • Insulin lispro
  • Postprandial hyperglycemia
  • Quality of life

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmaceutical Science
  • Pharmacology

Cite this

Management of diabetes mellitus with insulin lispro. / Tanaka, Masami; Itoh, Hiroshi.

In: Clinical Medicine Insights: Therapeutics, Vol. 3, 2011, p. 275-289.

Research output: Contribution to journalArticle

@article{514c02293b564677b5c469cb7838598d,
title = "Management of diabetes mellitus with insulin lispro",
abstract = "Insulin lispro (Humalog{\circledR}) is a recombinant human insulin analogue with reversed amino acids at position 28 and 29 on the insulin B-chain (Lys(B28), Pro(B29)). It has a faster onset and shorter duration of glucose-lowering activity than regular human insulin (RHI), which is a great advantage. Insulin lispro can be injected immediately before meals or even after meals. This short injection-meal interval contributes greatly to convenience, flexibility, treatment compliance, and patients' quality of life, which in turn lead to better glycemic control. Numerous clinical trials have demonstrated that insulin lispro, alone or as mixture-25 or -50, controls postprandial blood glucose and stabilizes diurnal variation satisfactorily. The risk of hypoglycemia, including severe or nocturnal episodes, was lower in insulin lispro users than in RHI users. This insulin might be suitable for type 1 diabetic patients, especially when using an insulin pump. Combination therapy of lispro with a sulphonylurea or glargine is safe and efficacious. Several pharmacoeconomic studies have revealed the usefulness of this insulin.",
keywords = "Diabetes mellitus, Hypoglycemia, Insulin lispro, Postprandial hyperglycemia, Quality of life",
author = "Masami Tanaka and Hiroshi Itoh",
year = "2011",
doi = "10.4137/CMT.S1155",
language = "English",
volume = "3",
pages = "275--289",
journal = "Clinical Medicine Insights: Therapeutics",
issn = "1179-559X",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Management of diabetes mellitus with insulin lispro

AU - Tanaka, Masami

AU - Itoh, Hiroshi

PY - 2011

Y1 - 2011

N2 - Insulin lispro (Humalog®) is a recombinant human insulin analogue with reversed amino acids at position 28 and 29 on the insulin B-chain (Lys(B28), Pro(B29)). It has a faster onset and shorter duration of glucose-lowering activity than regular human insulin (RHI), which is a great advantage. Insulin lispro can be injected immediately before meals or even after meals. This short injection-meal interval contributes greatly to convenience, flexibility, treatment compliance, and patients' quality of life, which in turn lead to better glycemic control. Numerous clinical trials have demonstrated that insulin lispro, alone or as mixture-25 or -50, controls postprandial blood glucose and stabilizes diurnal variation satisfactorily. The risk of hypoglycemia, including severe or nocturnal episodes, was lower in insulin lispro users than in RHI users. This insulin might be suitable for type 1 diabetic patients, especially when using an insulin pump. Combination therapy of lispro with a sulphonylurea or glargine is safe and efficacious. Several pharmacoeconomic studies have revealed the usefulness of this insulin.

AB - Insulin lispro (Humalog®) is a recombinant human insulin analogue with reversed amino acids at position 28 and 29 on the insulin B-chain (Lys(B28), Pro(B29)). It has a faster onset and shorter duration of glucose-lowering activity than regular human insulin (RHI), which is a great advantage. Insulin lispro can be injected immediately before meals or even after meals. This short injection-meal interval contributes greatly to convenience, flexibility, treatment compliance, and patients' quality of life, which in turn lead to better glycemic control. Numerous clinical trials have demonstrated that insulin lispro, alone or as mixture-25 or -50, controls postprandial blood glucose and stabilizes diurnal variation satisfactorily. The risk of hypoglycemia, including severe or nocturnal episodes, was lower in insulin lispro users than in RHI users. This insulin might be suitable for type 1 diabetic patients, especially when using an insulin pump. Combination therapy of lispro with a sulphonylurea or glargine is safe and efficacious. Several pharmacoeconomic studies have revealed the usefulness of this insulin.

KW - Diabetes mellitus

KW - Hypoglycemia

KW - Insulin lispro

KW - Postprandial hyperglycemia

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=80053594596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053594596&partnerID=8YFLogxK

U2 - 10.4137/CMT.S1155

DO - 10.4137/CMT.S1155

M3 - Article

VL - 3

SP - 275

EP - 289

JO - Clinical Medicine Insights: Therapeutics

JF - Clinical Medicine Insights: Therapeutics

SN - 1179-559X

ER -